Decision: Favourable
Study Title:
A Phase 1/2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR- 707) combined with cemiplimab for the treatment of participants with advanced unresectable or metastatic skin cancers
NREC Code:
21-NREC-CT-069
Decision:
Favourable
Meeting Date:
11/08/2021
Study Type:
CT application
Principal Investigator:
Prof John Crown
PI Institution:
St Vincent's University Hospital
Sponsor:
Sanofi-aventis Recherche & Développement